Spectral Medical Inc T.EDT

17k CHDF/PMX patients, SIGNIFICANT 28 day surv. rate w. PMX

[mercedesman]

April 22, 2021

Abstract

This study investigated sepsis patients' current status with continuous hemodiafiltration (CHDF) with or without polymyxin B hemoperfusion (PMX). We identified 17,367 adult sepsis patients treated with CHDF and PMX using the Japanese diagnosis procedure combination database (DPC) from April 2016 to March 2019. More than half of the patients in this category resulted in death in the hospital, which means that patients in this group were critically ill. Among the patients who received CHDF, the 28day survival rate of PMXtreated patients was significantly higher than that of nontreated patients, after adjusting the patient background by propensity score matching (69.5% vs. 65.4%, p<0.0001). Furthermore, the length of hospital stay and ICU stay was significantly shorter in PMXtreated patients than that of nontreated patients. These results suggest that PMX may provide benefits to patients with severe sepsis requiring CHDF.

https://onlinelibrary.wiley.com/doi/abs/10.1111/1744-9987.13655

MM

[Domino55]

MM-in layman terms it means?

[mercedesman]

IMHO it means: that PMX is for real - due to a VERY LARGE Japanese study that shows lives are being saved with PMX. more Real World Evidence for the FDA to chew on when it deliberates over Tigris that Spectral is a bona fide two trick pony (each with a potential market well over $ 1B) shorened hospital stays suggests meaningful healthcare cost reductions (insurance co's will

[Domino55]

I meant the specifics of the study itself but I see what you are getting at. thanks